enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 2.81M
Average 1.58M
ENGN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
enGene Holdings Inc.NASDAQ: ENGN
Cash & Equivalents · Q2 FY2026 · quarter ended Apr 2026
Cash & equivalents falls 48.2% from a year ago
Cash & equivalents stood at $29.83M at the end of Q2 FY2026, down 48.2% from a year earlier and down 18.5% from the prior quarter. Over 3 fiscal years it compounded at +442.5% a year.
Context
- Cash & equivalents amounted to 9.7% of total assets at the end of Q2 FY2026, down 11.9 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -48.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 50.15M USD
- Year-over-year change
- -71.0%
- 4-year CAGR
- +161.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 50.15M | -71.0% |
| FY2024 | 2024-10-31 | 173M | +112.2% |
| FY2023 | 2023-10-31 | 81.52M | +25849.6% |
| FY2022 | 2022-10-31 | 314.15K | -70.6% |
| FY2021 | 2021-10-31 | 1.07M | — |
Cash & Equivalents vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -48.2% is the 9th highest of 11, against a peer median of +36.9%.
- Cash & equivalents amounts to 9.7% of total assets for ENGN, versus a peer median of 31.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $263.76M USD | +64.1% | +54.0% | 95.5% | |
| Mar 2026 | $229.2M USD | +1668.2% | -2.5% | 86.0% | |
| Mar 2026 | $177.91M USD | +742.2% | +47.1% | 85.3% | |
| Mar 2026 | $175.21M USD | +80.4% | +5.0% | 66.6% | |
| Mar 2026 | $131.06M USD | +9.7% | -14.7% | 20.3% | |
| Mar 2026 | $97.6M USD | +98.8% | -26.7% | 29.1% | |
| Mar 2026 | $61.7M USD | -3.8% | -16.1% | 33.6% | |
| Mar 2026 | $35M USD | -72.6% | -10.9% | 12.1% | |
ENGNenGene Holdings Inc. | Apr 2026 | $29.83M USD | -48.2% | +442.5% | 9.7% |
| Mar 2026 | CHF 19.17M CHF | -4.0% | -5.3% | 13.9% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding ENGN) | — | +36.9% | -8.1% | 31.3% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.07M | 314.15K | 81.52M | 173M | 50.15M |
| Short-term Investments | 0 | 0 | 76K | 65.4M | 143.66M |
| Net Receivables | 0 | 0 | 2.34M | 1.03M | 2.23M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 1.5M | 7.93M | 5.35M |
| Total Current Assets | 1.57M | 511.8K | 85.44M | 247.36M | 201.39M |
| Property, Plant & Equipment (Net) | 0 | 0 | 589K | 2.91M | 10.19M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 129.67M | 131.53M | 70K | 59.53M | 8.52M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 209.05K | 939K | 860K | 1.37M | 1.36M |
| Total Non-current Assets | 129.88M | 131.53M | 1.52M | 63.81M | 20.08M |
| Total Assets | 131.45M | 132.04M | 86.96M | 311.17M | 221.47M |
| Account Payables | 0 | 0 | 1.16M | 1.41M | 6.69M |
| Short-term Debt | 1.05M | 1.27M | 562K | 1.12M | 10.02M |
| Tax Payables | 0 | 22K | 39K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 327.45K | 893.51K | 2.69M | 8.65M | 11.2M |
| Total Current Liabilities | 327.45K | 893.51K | 5.26M | 14.66M | 31.98M |
| Long-term Debt | 0 | 0 | 9.22M | 22.47M | 15.32M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 3.73M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 3.73M | 0 | 0 | 0 |
| Total Non-current Liabilities | 3.73M | 3.73M | 9.22M | 23.9M | 21.78M |
| Total Liabilities | 4.05M | 4.62M | 14.47M | 38.56M | 53.76M |
| Common Stock | 129.67M | 131.53M | 259.37M | 509.81M | 513.28M |
| Retained Earnings | (2.28M) | (4.11M) | (199.59M) | (254.73M) | (372.03M) |
| Accumulated OCI | 0 | 0 | (1.02M) | (1.42M) | (888K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 127.39M | 127.42M | 72.49M | 272.61M | 167.71M |
| Total Debt | 4.16M | 32.11M | 9.78M | 25.02M | 31.8M |
| Net Debt | (1.07M) | (314.15K) | (71.74M) | (147.98M) | (18.36M) |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.